TIDMMTPH

RNS Number : 0106E

Midatech Pharma PLC

08 March 2022

8 March 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Appointment of Nominated and Financial Adviser

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.

Turner Pope Investments (TPI) Ltd will be the Company's sole broker.

For further information, please contact:

 
 Midatech Pharma PLC 
  Stephen Stamp, CEO, CFO 
  Tel: +44 (0) 29 2048 0180 
  www.midatechpharma.com 
 
 Strand Hanson Limited (Nominated and Financial Adviser) 
  James Dance / Matthew Chandler / Rob Patrick 
  Tel: +44 (0)20 7409 3494 
 
 Turner Pope Investments (TPI) Ltd (Broker) 
  Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
  Tim Metcalfe / Graham Herring 
  Tel: +44 (0)20 3934 6630 
  Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Alyssa Factor 
  Tel: +1 (860) 573 9637 
  Email: afactor@edisongroup.com

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

-- Q-Sphera(TM) platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

-- MidaSolve(TM) platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

-- MidaCore(TM) platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPGCGDXIDGDGDI

(END) Dow Jones Newswires

March 08, 2022 04:30 ET (09:30 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.